CytoDyn starts metastatic triple negative breast cancer trial

CytoDyn is pleased to announce that on November 23, 2018, it received FDA approval of its IND submission and is allowed to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast cancer, TNBC, patients. CytoDyn has identified five clinical trial sites and intends to dose its first several patients and expects to have initial readout during the first quarter of 2019. The change in circulating tumor cells number will be evaluated every 21 days during treatment and will be used as an initial prognostic marker for efficacy. Up to 48 patients are expected to be enrolled in this study. The company presented Dr. Pestell’s research which showed three key properties of the CCR5’s Mechanism of Action. The first is that the CCR5 receptor on cancer cells was responsible for the migration and invasion of cells into the blood stream, which leads to metastasis of breast, prostate, and colon cancer. The second is that blocking the CCR5 also turns on anti-tumor fighting properties restoring immune function. The third key finding was that blockage of the CCR5/CCL5 interaction had a synergistic effect with chemotherapeutic therapy and controlled cancer progression
https://thefly.com/landingPageNews.php?id=2828121